Medtech Q1 Earnings: What the Major Strategics Are Telling Us

With Q2 already underway, the latest medtech Q1 earnings reports offer an early read on where major strategics are gaining momentum, where pressure is building, and what strategic priorities are becoming clearer.

This quarter’s results point to a consistent theme: focused portfolios are outperforming broader platforms. Companies concentrated in clearly defined growth markets, particularly cardiovascular/structural heart, are delivering stronger execution. More diversified players remain highly competitive, but they are managing a wider mix of operational, integration, and macroeconomic challenges.

A closer look at the numbers makes that trend difficult to ignore.

Focused Players Continue to Separate Themselves

Abbott delivered $5.5 billion in Q1 Medical Devices revenue, representing 8.5% organic growth and 13.2% reported growth year over year. Electrophysiology, Rhythm Management, and Heart Failure each posted double-digit gains, while the U.S. launch of Volt supported EP performance. Continuous glucose monitors contributed $2 billion of the quarterly total.

Still, softer U.S. prescription demand in diabetes care, delayed international tenders, and investor concerns around slowing organic momentum weighed on sentiment. The Exact Sciences acquisition also introduces integration complexity.

Boston Scientific generated $5.2 billion in Q1 revenue, up 9.4% organically and 11.6% reported. Cardiovascular remained the growth engine, climbing 13.5%. However, management reduced guidance from 10%–11% growth to 6.5%–8%, reflecting pressure across electrophysiology, WATCHMAN, and urology.

The EP story is especially notable. After benefiting from an early pulsed-field ablation advantage, Boston Scientific is now facing intensifying competition. Meanwhile, acquisition integration remains uneven, with Axonics experiencing commercial disruption while Valencia Technologies may provide support to urology over time.

Edwards Lifesciences posted one of the strongest quarters among peers, reaching $1.7 billion in revenue with 16.7% reported growth. Performance exceeded expectations across segments, prompting management to raise full-year guidance to 9%–11%.

TAVR growth of 14.4% stands out, given the maturity of that segment. Strong clinical evidence supporting earlier intervention continues to expand the addressable market, and Edwards appears well-positioned to apply that strategy in adjacent structural heart categories.

Medtech Q1 Earnings Reveal The Value Of Portfolio Discipline

Intuitive continues to execute at an exceptionally high level. Q1 revenue climbed 23% year over year to $2.8 billion, exceeding estimates by nearly 6%. da Vinci procedure volumes reached approximately 874,000 cases, while Ion volumes climbed to roughly 43,000 procedures. da Vinci 5 placements nearly doubled, reaching 232 for the quarter.

Challenges remain in China and Japan, where domestic competition, pricing pressure, and low tender activity are weighing on performance. U.S. bariatric procedures also declined about 10%, reflecting the continued impact of GLP-1 adoption.

Even so, management raised procedure growth expectations for the year, an important signal for future recurring revenue.

Insulet reported 33.9% revenue growth, reaching $762 million. International Omnipod sales jumped nearly 60%, and guidance was raised again.

Yet despite strong operating performance, shares fell sharply following results. An unusual $87 million expense, a voluntary recall, concerns about competitive dynamics, and expectations that had climbed even higher all contributed to investor disappointment.

Larger Platforms Are Repositioning for Growth

Johnson & Johnson’s medtech business delivered $8.6 billion in Q1 sales, up 7.7% reported. Cardiovascular growth of 14.4% remains the standout, reinforcing the company’s strategic shift toward higher-growth cardiac assets. The Atraverse Medical acquisition and continued OTTAVA development support that direction.

Medtronic’s latest quarter, reported on a non-calendar schedule, showed $9.0 billion in revenue and 8.7% reported growth. Cardiovascular climbed 11%, while Cardiac Ablation Solutions surged 80% globally and 137% in the U.S., driven by pulsed-field ablation.

The company’s recent business development activity also suggests an increasingly aggressive posture, with the Pulnovo investment further highlighting areas of focus.

Stryker’s quarter is harder to isolate due to a three-week cybersecurity disruption. Reported growth came in at 2.6%, with MedSurg and Neurotechnology up 5.0% and Orthopedics up 4.1%. Management expects lost revenue to recover throughout the year.

Longer term, Stryker’s endovascular strategy bears watching. With Inari integration underway and the Amplitude Vascular Systems acquisition expanding capabilities, the company appears to be assembling a larger strategic position.

The Strategic Takeaway

The strongest performers in medtech Q1 earnings were not necessarily the biggest companies. They were the ones with the clearest strategic identity.

Edwards remains tightly aligned around structural heart. Intuitive dominates robotic surgery. Insulet continues to lead in tubeless insulin delivery.

The diversified strategics are not standing still. Many are actively reallocating capital, reshaping portfolios, and leaning further into growth markets.

That likely sets the stage for continued medtech M&A activity as 2026 progresses.

Execution, not ambition, will determine who separates from the pack.